Cullinan Therapeutics (CGEM) CMO sells shares to cover RSU tax bill

Rhea-AI Filing Summary

Cullinan Therapeutics Chief Medical Officer Jeffrey Alan Jones reported an open-market sale of 4,582 shares of common stock at $14.47 per share. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, Jones directly holds 159,968 shares of Cullinan Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Jeffrey Alan

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		S(1)		4,582	D	$14.47	159,968	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cullinan Therapeutics (CGEM) disclose for Jeffrey Alan Jones?

Cullinan Therapeutics reported that Chief Medical Officer Jeffrey Alan Jones sold 4,582 shares of common stock. The shares were sold in an open-market transaction and the filing notes the sale was made to cover personal income tax obligations from vesting restricted stock units.

At what price did the Cullinan Therapeutics (CGEM) CMO sell shares in this Form 4?

Jeffrey Alan Jones sold 4,582 shares of Cullinan Therapeutics common stock at $14.47 per share. This price reflects the average sale price reported for the open-market transaction disclosed in the Form 4 insider trading report.

How many Cullinan Therapeutics (CGEM) shares does the CMO hold after this Form 4 sale?

Following the reported sale, Chief Medical Officer Jeffrey Alan Jones directly holds 159,968 shares of Cullinan Therapeutics common stock. This share count is reported as the total beneficial ownership immediately after the open-market sale to cover tax obligations.

Why did the Cullinan Therapeutics (CGEM) CMO sell 4,582 shares according to the Form 4?

The Form 4 footnote states the 4,582-share sale was executed to cover personal income tax obligations. These obligations arose upon the vesting of restricted stock units previously granted to Chief Medical Officer Jeffrey Alan Jones by Cullinan Therapeutics.

Is the Cullinan Therapeutics (CGEM) insider transaction classified as a buy or sell?

The transaction is classified as a sell. The Form 4 lists transaction code “S,” describing an open-market or private sale, and specifies that 4,582 shares of Cullinan Therapeutics common stock were sold by Chief Medical Officer Jeffrey Alan Jones.

What role does Jeffrey Alan Jones hold at Cullinan Therapeutics (CGEM) in this Form 4 filing?

In the Form 4, Jeffrey Alan Jones is identified as an officer of Cullinan Therapeutics, serving as Chief Medical Officer. The reported 4,582-share open-market sale and resulting ownership of 159,968 shares relate to his status as a company officer.